AT PATIENT TESTING® is a registered trademark of BG Research Ltd (2025)
Imagine.....
- A deployable and scalable strategy,
- for delivering actionable results,
- in 30 minutes, at the Point of Decision,
- and so helping to improve global health outcomes
- – but most importantly save lives
Lab-grade sensitivity and specificity molecular diagnostics, performed directly from crude samples e.g. saliva, swabs and including whole, unprocessed blood — without extraction, lab infrastructure, or expert personnel.
Designed for both humans and veterinary use, and deployable in labs or in-field. Actionable results, enables early triage, intervention and outbreak control.
One Health utility — all at minimal Full Economic Cost.
- Innovative Diagnostics, Engineered for Purpose
- Portable… Specific…. Sensitive
Truly portable design. Built for real-world diagnostics—from outbreak management to frontline care.
CENOS™ is an innovative molecular diagnostics platform (comprising patent pending instrument and reagent chemistry) that delivers gold-standard real-time PCR results in 30 minutes—directly from crude samples, including blood, with no need for nucleic acid extraction.
CENOS™ operates without traditional lab infrastructure, enabling high-sensitivity and specificity testing in field settings, mobile units or even in central labs for urgent sample testing— delivering actionable results at the Point-of-Decision—where speed, accuracy, and insight, drive response.
- One Health.
- One Planet.
- .....Our Solution
CENOS™ is a next-generation real-time PCR diagnostics platform designed to support the One Health approach—detecting viral pathogens across humans, animals, vectors, and environmental reservoirs.
These interconnected systems demand a unified response. CENOS™ enables early, accurate detection at critical points—supporting disease surveillance and response before outbreaks spread.
One Platform. Cross-Species Surveillance. Global Impact.